Inclusion Criteria:  Age >18 years old at the time of study entry Can provide written informed consent Patients who are currently receiving standard of care systemic anti-cancer therapy (chemotherapy, immunotherapy, endocrine and targeted therapy) for solid organ malignancy and have received at least one cycle Sufficient hearing to be able to participate in a video training session  Exclusion Criteria:  Known inherited or acquired bleeding disorder History of haematological malignancy Known poorly controlled anti-coagulation Inadequate use and understanding of the English language, requiring a translator Participant unlikely to be able to perform fine manipulation required to use lancet or cartridge to obtain capillary blood sample and result Previously taken part in the 'PERTH-2' study involving a prototype device